Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acorda Therapeutics

- PMLiVE

Biogen trumpets safety data for Tecfidera follow-up

Much riding on blockbuster's successor

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Pfizer’s alliance with Sosei Heptares bears first fruit

Partners focusing on GPCR-targeting drugs

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Speedy approval for Pfizer’s Onpattro rival

Approved in two different formulations

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

- PMLiVE

Solid Q1 results lift Pfizer as it waits for pipeline boost

Shares rose almost 2% in the wake of the presentation

- PMLiVE

Biogen’s Spinraza overpriced, says ICER

Cost watchdog warns high price puts pressure on US health system

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links